SynthesisFrontiers in immunology2026
Diagnostic accuracy of
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Latent tuberculosis infection (LTBI) affects nearly a quarter of the world's population, yet current diagnostic tools are suboptimal. Interferon-γ-inducible protein 10 (IP-10) has been proposed as a candidate biomarker, but its diagnostic value for LTBI among high-risk groups is unclear. To address this, we performed a systematic review and meta-analysis to assess the accuracy of Methods: PubMed, Web of Science, Embase, Scopus, and the Cochrane Library were searched up to April 2026. Cohort and cross-sectional studies evaluating Mtb antigen-induced IP-10 for LTBI diagnosis in high-risk groups were included. A bivariate random-effects model and a hierarchical summary receiver operating characteristic model were used to estimate and summarize the overall diagnostic performance. Results: Nineteen articles comprising 24 studies (2,014 participants) were included. The pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and area under the curve of Mtb antigen-induced IP-10 were 0.81, 0.88, 6.93, 0.21, 32.56, and 0.91, respectively, indicating good diagnostic performance of Mtb antigen-induced IP-10 for detecting LTBI among high-risk groups. The bivariate boxplot, meta-regression and subgroup analysis identified no significant source of heterogeneity. Conclusion: Mtb antigen-induced IP-10 is a promising biomarker for detecting LTBI among high-risk groups. It may serve as a useful adjunct to IGRAs and TST, although its clinical utility requires further validation. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261388089.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.